REGENXBIO/$RGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About REGENXBIO

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Ticker

$RGNX
Sector
Primary listing

Employees

353

REGENXBIO Metrics

BasicAdvanced
$490M
-
-$3.43
1.11
-

What the Analysts think about REGENXBIO

Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.

Bulls say / Bears say

Closed a non-dilutive royalty bond deal that brings in $150 million upfront and gives the company funding into early 2027, lessening dilution risk and supporting late-stage programs with no new equity (PRNewswire)
FDA accepted the BLA for RGX-121 with Priority Review, setting a PDUFA date of November 9, 2025. This establishes the first-in-class, one-time gene therapy for MPS II as a near-term growth driver (PRNewswire)
Interim data from the Phase I/II AFFINITY DUCHENNE trial show RGX-202 participants surpassing matched natural history controls in key motor functions and no serious adverse events, supporting its strong profile and the move into accelerated pivotal testing (PRNewswire)
Pivotal data for ABBV-RGX-314 in wet AMD—a major partnered program with AbbVie—won’t be available until 2026, pushing back hopes for royalties or commercial returns to the medium term (PRNewswire)
The pivotal AFFINITY DUCHENNE trial for RGX-202 is only about halfway enrolled as of Q1 2025. The company doesn’t expect to file its BLA until mid-2026, so any revenue from Duchenne gene therapy likely won’t come until late 2026 or later (PRNewswire)
REGENXBIO is dependent on its partner Nippon Shinyaku to bring RGX-121 to market in key areas, which could narrow margins and adds the risk of execution or royalty shortfalls when approved (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2025.

REGENXBIO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

REGENXBIO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGNX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs